Alcon Announces its Largest-Ever Scientific Program at the 41st Congress of the ESCRS, Showcasing New Data and Innovation to Support Ophthalmic Surgical Teams
07 September 2023 - 6:30AM
Business Wire
- Alcon innovations featured in more than 75 abstracts across
cataract, refractive, visualization and ocular health1
- Clinical data presentations and sponsored symposia to
highlight the efficacy of Alcon’s intraocular lens and surgical
equipment portfolio
- Booth activations to feature expert discussions and demos
with Alcon’s latest innovation, including wavelight plus, the next
generation in refractive surgery, which has now received CE mark
approval
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, will present a robust lineup of
scientific data at the 41st Congress of the European Society of
Cataract and Refractive Surgeons (ESCRS), happening 8-12 Sept. in
Vienna, Austria. Alcon will showcase product updates that deliver
patient outcomes and operational efficiencies for ophthalmologists
and staff, and host events with surgeons sharing their real-world
experiences with Alcon’s innovation, at booth #B201. For every
attendee’s badge scanned at the Alcon booth, Alcon will further its
commitment to environmental sustainability by funding the
collection and recycling of 50 plastic bottles in coastal
communities as part of its ongoing Plastic Bank partnership. Alcon
ESCRS event information and registration is available at
MyAlconatESCRS.com.
“Alcon is driven by our purpose to help people see brilliantly.
Introducing cutting-edge innovation and breakthrough technology has
helped us bring our purpose to life for more than 75 years,” said
Sunil Vasanth, VP, Europe Surgical Franchise, Alcon. “As the
leading eye care device company, we are proud to share new data and
information that will help surgeons achieve brilliant
outcomes.”
Timed with ESCRS, Alcon will also expand its Global Medical
Affairs website, www.AlconScience.com, to now support eye care
professionals in Brazil, Canada, Germany, India, Italy, Spain, U.K.
and the U.S. AlconScience.com consolidates information about
Alcon’s scientific, academic and related activities into one
portal. Visitors may download clinical science publications, submit
grant applications for Investigator-Initiated Trials (IITs) and
apply for independent medical education support, among other
activities.
Data bolsters efficacy of Alcon’s
surgical portfolio offerings*
Leading experts will present scientific abstracts and papers
based on their experiences with Alcon’s innovation, including an
exploratory, randomized, parallel group study evaluating the impact
of cataract surgery and IOL implantation using the Centurion®
Vision System with Active Fluidics™ and Active Sentry® handpiece on
intraocular pressure (IOP).2 'Evaluation of early changes of the
anterior vitreous interface after cataract surgery, using low
pressure settings determined by OCT,’ Dr. Hugo Scarfone
(Argentina), Fri., 8 Sept. (on-demand e-poster session).
Additional studies of note include:
- ‘A comparative evaluation of two extended depth-of-focus
intraocular lenses (EDOFs) in cataract surgery: results of a
prospective randomized trial,’ Dr. Maria Mazzoni (Italy), Fri., 8
Sept., (on-demand e-poster session)3
- ‘Visual performance and patient reported visual disturbances
with two presbyopia-correcting intraocular lenses; a randomized
bilateral study,’ Dr. Satish Modi (United States), Tues., 12 Sept.,
08:30-08:36 CEST4
- ‘Femtosecond-laser assisted myopic LASIK customized by
automated ray-tracing calculation of low and high order
aberrations: a prospective, international multicenter, post-market
study,’ Dr. John Kanellopoulos (Greece), Mon., 11 Sept.,
09:42-09:48 CEST5
Alcon to host a number of events during
ESCRS
As part of the official ESCRS scientific program, Alcon will
host three satellite symposia and a number of booth talks. Symposia
will cover topics of interest such as the evolving role of digital
and 3D visualization, the clinical impact of IOP, astigmatism
management, and IOL selection based on patients’ needs and
expectations. At our booth talks, renowned surgeons will share
their experiences and best practices for cataract surgery—covering
topics on equipment ecosystem connectivity with the Alcon Vision
Suite, IOL options and selection, and benefits of surgery at more
physiologic IOP. Speaker information and details on these events
are available at MyAlconatESCRS.com.
Alcon continues to demonstrate
leadership in surgical ophthalmology through additional sponsorship
initiatives
- Alcon is again a platinum sponsor for the ESCRS iNovation Day
on Fri., 8 Sept., where experts from around the world will discuss
urgent clinical needs and barriers to success in anterior segment
care.
- Alcon will sponsor three near-live surgery sessions on Sat., 9
Sept., from 14:00-16:00. Mr. Bruce Allan (UK), Prof. Dr. Rudy
Nuijts (Netherlands) and Dr. Vincenzo Maurino (UK) will perform
cataract surgery with the Alcon Vision Suite and Alcon IOLs.
- Alcon is proud to join the ESCRS in taking a bold stand for
sustainability. Check out Alcon’s 2022 Social Impact and
Sustainability Report to learn more about the company’s ongoing ESG
initiatives and progress.
For more details on all Alcon ESCRS activities, click
here.
Please refer to relevant products DFU or Operator’s manuals for
complete list of indications, contraindications and warnings.
Products mentioned may not be approved in all markets; please
reach out to your Alcon Rep for questions about availability in
your local market.
This content is intended for Healthcare Professionals (HCPs)
only. Please note that product-related promotion of Medical Devices
to non-HCPs may be subject to restrictions based on local rules and
regulations.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 25,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
*These investigator-initiated studies were supported by
Alcon.
References
- Alcon. Data on File. 2023.
- Scarfone H, et. al. Evaluation of Early Changes of the Anterior
Vitreous Interface after Cataract Surgery, Using Low Pressure
Settings Determined by OCT. Presented at the European Society of
Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept,
2023; Vienna, Austria.
- Mazzoni M, et. al. A Comparative Evaluation of Two Extended
Depth-of-Focus Intraocular Lenses (EDOFs) in Cataract Surgery:
Results of a Prospective Randomized Trial. Presented at the
European Society of Cataract and Refractive Surgery (ESCRS) Annual
Meeting; 8-12 Sept, 2023; Vienna, Austria.
- Modi S, et. al. Visual Performance and Patient Reported Visual
Disturbances with Two Presbyopia-Correcting Intraocular Lenses; A
Randomized Bilateral Study. Presented at the European Society of
Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept,
2023; Vienna, Austria.
- Kanellopoulos J, et. al. Femtosecond-Laser Assisted Myopic
LASIK Customized by Automated Ray-Tracing Calculation of Low and
High Order Aberrations: A Prospective, International Multicenter,
Post-Market Study. Presented at the European Society of Cataract
and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept, 2023;
Vienna, Austria.
Connect with us on
Facebook LinkedIn X
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906464858/en/
Investor Relations Allen
Trang + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Cara
Jones-Faye + 41 79 93 3811 Cara.Jones_Faye@Alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Apr 2024 to May 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From May 2023 to May 2024